Headline Maker: Exploration Investor notices the excitment surrounding Nexia Holdings, Inc

Oct 24, 2007 (M2 PRESSWIRE via COMTEX) -- NEXA | charts | news | PowerRating -- Exploration Investor strives to provide you with outstanding market results. We will be your number one resource for all your small and large cap needs. While working to keep you in touch with market activity, we also will keep you updated on the latest press.

This morning, October 24, 2007, AmeriResource Technologies, Inc. (OTCBB:AMRE) announced that it has closed on the sale of 90% of the issued and outstanding stock of Green Endeavors LTD.(OTCPK:GRNE) in exchange for the issuance of 150,000 shares of restricted Series C Preferred stock of Nexia Holdings, Inc.(OTCBB:NEXA) with a stated value of $5.00 per share. Green Endeavors LTD. will retain 13 million shares of BizAuctions, Inc. (OTCPK:BZCN) restricted common stock and $171,000 in debt.

Mr. Janovec pointed out that, "AMRE will benefit by becoming a shareholder in Nexia and retaining a minority shareholder interest in GRNE. Upon GRNE acquiring Landis LLC, AMRE will reap the benefits of being a shareholder in GRNE's operations that are on track to generate $2.3M in gross revenues in 2007. GRNE has plans to grow its operations significantly. In addition, AMRE will eliminate the costs and time associated with maintaining the public status of GRNE which will free up resources that will be redirected into growing revenues for BizAuctions, Inc. and AMRE's other operations."

The transaction with Nexia has further created the potential for a strategic alliance between BizAuctions, Inc. and Nexia's Black Chandelier clothing company. The alliance would involve BizAuctions selling Black Chandelier's excess inventory through its on-line eBay auction platform. This alliance will provide another revenue stream which expands its present auction platform of products that is available to on-line consumers.

Richard Surber, CEO of Nexia Holdings, Inc., commented, "Mr. Janovec is a visionary. He realizes that Nexia is a ground level investment opportunity. Mr. Janovec has seized upon an opportunity that streamlines AMRE's operations and diversifies AMRE's portfolio. I am confident that AMRE will benefit from the acquisition of Nexia's Class C preferred stock as well as realize the benefit of increased value of its remaining GRNE shareholdings. Nexia's plans for GRNE will benefit AMRE and all GRNE shareholders. Over the coming weeks, Delmar and I will be working hard to build value through additional alliances between BZCN and Black Chandelier which could result in BZCN selling our high quality apparel creating another mutually beneficial transaction."

Nexia Holdings was also very pleased to announce that they have teamed with The Afghanistan Orphanage Project ("TAO Project") to assist in community outreach and promotions. The TAO Project filmed a promotional video at Globus Relief, the weekend of October 13, 2007, in honor of their 501(c)3 stamp of approval from the IRS, effective August 22, 2007. Nexia and Landis sponsored the event, providing a catered meal and professional hair and makeup services for the staff, including the reigning Miss Utah and TAO spokesperson Jill Stevens. Professional photography and portraiture was provided by Grant Heaton Productions. The event doubled as a social gathering for the community.

"We are honored to have their support," says Jared Jones, Chief Operations Officer of The Afghanistan Orphanage Project. "We certainly could not have done this without their help and are excited to move forward in our creative partnership."

Richard Surber, president of Nexia, said, "We are honored to help the team at TAO with their next promotional project. Their mission is a lofty one - to build one of the largest orphanages in Afghanistan. We look forward to helping them create an impactful promotional video that conveys the importance of their message." The TAO Project anticipates that the promotional will be posted to their website by November 15, 2007. The website will serve as a hub for viewers to track the progress of the documentary. Contributors will be given access to exclusive online content, to include weekly video journal updates and behind-the-scenes interviews.

Following these announcement shares of Nexia Holdings jumped up 100% to $0.0002 on decent volume of 20 million. We will continue to watch over this company and will report on any future developments pertaining to the company.

In other news, Immureboost (immureboost.com) presented a product at the Therapies for Viral Hepatitis Symposium to Boston Scientists. The Immureboost Company presented poster "Normalization of Elevated Liver Enzymes due to V-1 Immureboost Therapy" at the international symposium Therapies for Viral Hepatitis held in Boston on October 29-31, 2002. The abstract of the presentation is published in UK-based medical journal Antiviral Therapy (2002; Vol 7, L115-L116).

This work was a result of the collaboration with Dr. Orapun Metadilogkul of Rajavithi Public Hospital in Bangkok, Thailand. V-1 Immureboost (V1) is an oral therapeutic AIDS vaccine developed by Pharmacologist Mr. Vichai Jirathitikal. Immureboost is also licensed as a food supplement and as experimental R&D drug in Thailand.

V1 has been used by 60,000 AIDS patients in Thailand and 3,500 patients in 50 countries worldwide. Hepatitis is a serious and potentially life-threatening disease which may culminate in liver cancer. Hepatitis B causes 60% to 80% of the world's primary liver cancer with over one million people dying annually. Although preventive vaccines against some forms of hepatitis are available, they are only able to protect individuals who have not yet been infected. About 500 million individuals worldwide are infected with two major types of hepatitis B and C viruses. For those who are already infected, no effective and at the same time non-toxic and inexpensive therapy, is currently available.

Diagnosis of virally induced chronic hepatitis is often made when a patient presents elevated liver enzyme levels known as alanine (ALT or SGPT) and aspartate (AST or SGOT) aminotransferases. Many clinicians treat patients solely on the basis of clinical and biochemical abnormalities, i.e., elevated liver enzymes. Other clinical markers aiding the hepatitis diagnosis are abnormal levels of alkaline phosphatase and bilirubin.

Upon analysis of results of phase I study of V1 it has been discovered that HIV-positive patients who initially had higher than normal ALT and AST levels had experienced the reduction of enzyme levels back to normal. Similar reduction to normalcy was observed with two other markers of hepatitis, alkaline phosphatase and bilirubin. Separately, three patients who were Hepatitis B antigen positive became negative after V1 therapy. In contrast, patients who had normal baseline liver enzyme levels have not experienced any significant changes.

According to liver enzyme profiles the response rate to V-1 Immureboost therapy was about 95%.

This compares favourably with reported biochemical response of hepatitis to interferon (10-20%) or interferon and ribavirin combination (30-40%). New hepatitis drugs like GlaxoSmithKline is Lamivudine and Gileads Adefovir have fewer side-effects than interferon but they are still not ideal. The virus generally returns once treatment is stopped and keeping a patient on a life-long treatment is not an option since drug resistance and toxicity are major concerns. Importantly, a 48-week combination of interferon and ribavirin treatment costs nearly $20,000 per person. In contrast, V1 is much cheaper; one pill of V1 costs less than U$ 1 cent.

Thus, it is possible that V-1 Immureboost might be useful for treating hepatitis, especially when one considers the fact that immunogenic constituents of V1 are derived from HIV-infected donors many of whom are co-infected with hepatitis B and C viruses. In this sense V1 is similar to the first generation of commercial Hepatitis B vaccine, which contained pooled viral antigens derived from the blood of hepatitis B carriers. Immureboost is now seeking to pursue this intriguing observation in controlled studies by recruiting patients with confirmed HIV and hepatitis. In closing Immureboost has just become a public company and is listed on the NASDAQ BB under IMBO.OB.

The Financial Information and Financial Content provided by Explorationinvestor.com is for informational purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or endorsement, recommendations, or sponsorship of any company or security by Explorationinvestor.com. You acknowledge and agree that any request for information is unsolicited and shall neither constitute nor be construed as investment advice by Explorationinvestor.com to you. It is strongly recommended that you seek outside advice from a qualified securities professional prior to making any securities investment. Explorationinvestor.com does not provide or guarantee any legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or informational source.

All material herein was prepared by based upon information believed to be reliable. The information contained herein is not guaranteed by Exploration Investor to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Exploration Investor is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index